Large-scale cancer sequencing data enable discovery of rare germline cancer susceptibility variants. Here we systematically analyse 4,034 cases from The Cancer Genome Atlas cancer cases representing 12 cancer types. We find that the frequency of rare germline truncations in 114 cancer-susceptibility-associated genes varies widely, from 4% (acute myeloid leukaemia (AML)) to 19% (ovarian cancer), with a notably high frequency of 11% in stomach cancer. Burden testing identifies 13 cancer genes with significant enrichment of rare truncations, some associated with specific cancers (for example, RAD51C, PALB2 and MSH6 in AML, stomach and endometrial cancers, respectively). Significant, tumour-specific loss of heterozygosity occurs in nine genes (ATM, BAP1, BRCA1/2, BRIP1, FANCM, PALB2 and RAD51C/D). Moreover, our homology-directed repair assay of 68 BRCA1 rare missense variants supports the utility of allelic enrichment analysis for characterizing variants of unknown significance. The scale of this analysis and the somatic-germline integration enable the detection of rare variants that may affect individual susceptibility to tumour development, a critical step toward precision medicine.
Mingchao Xie, Michael Wendl, Ph.D., Mike McLellan, Kuan-lin Huang, Matthew A Wyczalkowski, Ph.D., Reyka Jayasinghe, Jie Ning, Qunyuan Zhang, Ph.D., Heather Schmidt, Robert Fulton, Joshua McMichael, Prag Batra, Maheetha Bharadwaj, Chris Miller, Ph.D., Krishna Kanchi, Jim Eldred, David Larson, Ph.D., Elaine R. Mardis, Ph.D., Timothy Ley, M.D., Richard K. Wilson, Ph.D., Li Ding, Ph.D.